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Mice with homozygous null mutations in the high-density lipoprotein
receptor SR-BI (scavenger receptor class B, type I) and apolipoprotein
E genes fed a low-fat diet exhibit a constellation of pathologies
shared with human atherosclerotic coronary heart disease (CHD):
hypercholesterolemia, occlusive coronary atherosclerosis, myocardial
infarctions, cardiac dysfunction (heart enlargement, reduced systolic
function and ejection fraction, and ECG abnormalities), and prema-
ture death (mean age 6 weeks). They also exhibit a block in RBC
maturation and abnormally high plasma unesterified-to-total choles-
terol ratio (0.8) with associated abnormal lipoprotein morphology
(lamellarvesicular and stacked discoidal particles reminiscent of
those in lecithincholesterol acyltransferase deficiency and cholesta-
sis). Treatment with the lipid-lowering, antiatherosclerosis, and an-
tioxidation drug probucol extended life to as long as 60 weeks (mean
36 weeks), and at 5–6 weeks of age, virtually completely reversed the
cardiac and most RBC pathologies and corrected the unesterified to
total cholesterol ratio (0.3) and associated distinctive abnormal li-
poprotein morphologies. Manipulation of the timing of administra-
tion and withdrawal of probucol could control the onset of death and
suggested that critical pathological changes usually occurred in un-
treated double knockout mice between 3 (weaning) and 5 weeks of
age and that probucol delayed heart failure even after development
of substantial CHD. The ability of probucol treatment to modulate
pathophysiology in the double knockout mice enhances the potential
of this murine system for analysis of the pathophysiology of CHD and
preclinical testing of new approaches for the prevention and treat-
ment of cardiovascular disease.
atherosclerosis  heart failure  myocardial infarction  unesterified
cholesterol
Coronary artery atherosclerosis is a major cause of myocardialinfarction (MI) and death. We have described a murine model
of human coronary heart disease (CHD) (1) that is based on
targeted homozygous null mutations in two genes whose products
play important roles in normal lipoprotein metabolism and protect
mice from atherosclerosis: the high-density lipoprotein (HDL)
receptor SR-BI (scavenger receptor class B, type I) (2, 3) and the
lipoprotein component apolipoprotein E (apoE) (4–7).
Low-fat chow-fed, homozygous null, apoE knockout (KO)
mice are hypercholesterolemic (4, 5), develop atherosclerosis
between 3 and 4 months of age, and usually live a long life (1
year), although older animals can sometimes develop coronary
artery occlusions and apparently associated pathology (8, 9).
SR-BI controls HDL structure and metabolism and appears to be
important for ‘‘reverse cholesterol transport,’’ HDL-mediated
transport of cholesterol from peripheral tissues (including athero-
sclerotic plaques) to the liver and then to the bile for excretion (2,
3, 10–16). SR-BI delivers cholesteryl esters and other lipids from
HDL to cells via selective lipid uptake (2, 3, 10, 17, 18) and can also
mediate unesterified cholesterol (UC) efflux from cells to HDL
(19–21). Homozygous null SR-BI KO mice fed a low-fat diet are
hypercholesterolemic (15) and exhibit abnormally low biliary cho-
lesterol excretion (50%) (13, 16), but apparently no spontaneous
atherosclerosis. Combined deficiencies of SR-BI and apoE (dKO)
result in increased cholesterol in very low-density lipoprotein
(VLDL)-sized and in abnormally large HDL-like particles and
dramatically accelerated atherosclerosis (4 weeks of age; ref. 16).
By 5–8 weeks of age dKO mice on a low-fat diet develop many
features of human CHD (occlusive atherosclerosis, MI, cardiac
dysfunction, death) (1, 16) and a cholesterol-dependent block in
RBC maturation (100% reticulocytosis) (22). The strikingly rapid
onset of a constellation of human-like cardiovascular pathologies in
dKO mice is not seen in most rodent models of hyperlipidemia and
atherosclerosis (1, 23, 24). Here we have treated dKO mice with the
lipid-lowering, antiatherosclerosis, and antioxidation drug probucol
(25–31) and shown that it dramatically prolonged their lives,
virtually completely reversed early-onset cardiovascular and most
RBC pathologies, corrected their abnormally high UC to total
cholesterol (TC) ratio (0.8 to 0.3) and prevented formation of
abnormal lipoproteins (lamellarvesicular and stacked discoidal
particles, rouleaux) reminiscent of those in lecithin–cholesterol
acyltransferase (LCAT) deficiency, cholestasis, and other cases of
high UCTC ratio (32–34). It appears that much of the probucol-
sensitive pathology was a consequence of postnatal (3–5 weeks of
age) processes. Manipulation of the time of probucol administra-
tion can be used as a switch or rheostat to start, arrest, or alter the
rate of progression of CHD in this model, which may be useful for
preclinical testing of new approaches for preventing and treating
cardiovascular disease.
Methods
Animals. Mice (mixed C57BL6  129 background) were main-
tained and fed a normal chow diet either with or without 0.5%
(wtwt) probucol supplementation [4,4,-(isopropylidene-
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dithio)-bis-(2,6-di-tert-butylphenol; Sigma] as described (15, 16,
35). Animal procedures were in accordance with Massachusetts
Institute of Technology institutional guidelines.
Morphologic, Biochemical, and Cardiac Functional Analyses. Histol-
ogy using frozen sections was performed as described (1, 16) or
with a minor modification of the method of Antos et al. (36).
Briefly, excised hearts were rinsed in PBS, incubated in Krebs–
Hanseleit solution without Ca2 to relax the cardiac muscle,
fixed in 10% formalin for 24 h at 4°C, and then infiltrated with
30% sucrosePBS for 24 h at 4°C. Samples were frozen in Tissue
Tek OCT (Sakura, Torrance, CA) and sectioned (10 m) before
staining with Masson’s trichrome (Sigma; ref. 1). Cholesterol,
phospholipid (PL), and triglyceride determinations were made
as described (16, 35) or with kits (Wako Chemical, Richmond,
VA). Two-dimensional and M-mode ECGs were performed by
using very light sedation (ketamine) (37). ECGs were recorded
noninvasively in conscious mice as described (1, 38) and analyzed
via E-MOUSE (Mouse Specifics, Boston). All other methods were
as described, including RBC characterization (22), FPLC plasma
fractionation (15, 16), gravimetry and MRI analyses (1), and
electron microscopy of phosphotungstic acid negatively stained
lipoproteins from plasma or FPLC fractions (34). No differences
were observed between males and females. A value of P  0.05
for differences was considered significant (two-tailed, unpaired
Student’s t test or ANOVA test for groups calculated with
Microsoft EXCEL or STATVIEW).
Results
Extension of dKO Life Span by Treatment with Probucol. To use dKO
mice as a model to test the influence of drugs on CHD and
premature death, we fed animals a low-fat diet supplemented
with probucol (0.5%). For two groups, probucol was adminis-
tered to mating pairs either before or at the time of mating and
continuously thereafter through weaning of offspring at 3–4
weeks of age (average age at weaning: 24.5 days). For one of
these groups, designated dKO-P, probucol feeding continued
throughout the animals’ lives. For the other group, designated
dKO-Pww (probucol withdrawn at weaning), only probucol-free
chow was provided after weaning.
Fig. 1A shows that probucol treatment substantially increased
the animals’ life spans: the median age of death for dKO-P mice
was 36 weeks (range 187–419 days), much more than 6 weeks
(35–56 days) for untreated animals. For dKO-Pww mice, the
median age of death was 13 weeks (80–123 days). Probucol is
lipophilic and may have been available from adipose stores (39)
in dKO-Pww mice for a short time after weaning.
We also administered probucol only after weaning, either
before 5 weeks (dKO-P5; mean age, 4.1 weeks, range 3.9–4.6
weeks) or later (dKO-P5; mean age, 5.2 weeks, range 5.1–5.3
weeks). Fig. 1B shows that the dKO-P5 mice lived far longer
(30.3 weeks, range 162–332 days) than untreated controls, but
not as long as the dKO-P group. The average life span of the
dKO-P5 group was 16 weeks (82–359 days), about half that of
the dKO-P5 mice, but more than double that of the untreated
controls. Thus, probucol treatment dramatically lengthened the
lives of dKO mice, the extent of which depended on the timing
and duration of administration. The findings suggest that sub-
stantial pathology that could be prevented or reversed by
probucol occurred between weaning and 5 weeks of age and that
the drug could extend life even when treatment began after
development of substantial CHD (dKO-P5 group, ref. 1).
Effects of Probucol Treatment on Heart Function and Structure. We
next determined whether probucol-induced extended life span was
associated with correction of functional and structural cardiac
defects at 5–6 weeks of age. Fig. 2A shows MRI short axis views
of the hearts at end diastole (Left) and end systole (Right). As
reported (1), the left ventricular end systolic volumes (LVESVs)
were abnormally high in untreated dKO hearts (Fig. 2A Upper
Right), resulting in a low ejection fraction (43  13% vs. 87  5%
for apoE KO; not shown, ref. 1). In contrast, LVESVs (Fig. 2A
Lower Right) and ejection fraction were essentially normal in
dKO-P (87.7  3.2%, n  5), compared with untreated dKO mice
(P  0.005; with no probucol effect in apoE KO mice, 85.6  2.0%,
n  3, P  0.57; ref. 1). In addition, the ST depression observed in
the ECGs of 50% of the untreated, unanesthetized dKO mice (1)
(e.g., Fig. 2B Upper) was eliminated by probucol treatment in 10 of
11 animals examined (e.g., Fig. 2B Lower, one of the dKO-P mice
exhibited a mild ST depression; data not shown).
Fig. 2C shows that probucol treatment prevented the abnor-
mal heart enlargement observed in untreated dKO, but not apoE
KO, mice (1). The significantly low body weight of dKOs at 6
weeks of age, 16.4  0.4 g [SEM, n  18 (1), P  0.0002,
ANOVA], was increased to 21.7  1.4 g (n  8), a value not
significantly different from those of apoE KO (21.8  1.6, n 
8) and probucol-treated apoE KO (22.4  1.3, n  4) controls.
Probucol’s effects on heart size were also readily apparent in
longitudinal histologic sections stained with Masson’s trichrome
(Fig. 3 A–C, n  3 for each group) and in preliminary echocar-
diographic analysis of wall thickness and left ventricle mass (data
not shown). Unlike the untreated dKO hearts (Fig. 3A), the sizes
and shapes of the dKO-P hearts (Fig. 3B) were essentially
indistinguishable from those of the untreated apoE KO controls
(Fig. 3C). Furthermore, the extensive MI (blue fibrotic tissue)
seen throughout the untreated dKO hearts was prevented by
Fig. 1. Effects of probucol on survival. (A) dKO mice (red line, n  13, chow
diet, ref. 1), dKO-P mice (blue line, n  10, 0.5% probucol diet from concep-
tion), and dKO-Pww mice (black line, n  9, probucol diet from conception
until weaning). (B) dKO-P5 mice (probucol diet administered only after
weaning but before 5 weeks of age, green line; n  9) and dKO-P5 (probucol
diet administered immediately after 5 weeks of age, purple line; n  7).
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probucol treatment. We did not observe in the dKO-P (and
either treated or untreated apoE KO) hearts the occlusive,
lipid-rich atherosclerotic plaques in coronary arteries (e.g., Fig.
3 E and F) or classic atherosclerosis in the root of the aortic sinus
(Fig. 3 G and H) seen in all untreated dKO mice (Fig. 3D and
refs. 1 and 16). Probucol’s effect on the aortic root in dKO mice
is noteworthy because, although it reduces aortic arch athero-
sclerosis (30) in older apoE single KO mice, it paradoxically
enhances aortic root atherosclerosis in apoE KO mice when
treatment is started at 2–4 months of age (28, 30). Probucol
treatment also does not reduce aortic root atherosclerosis in
fat-fed LDL receptor KO mice (40, 41). In summary, most of the
functional and morphologic indicators of occlusive atheroscle-
rotic coronary artery disease, MI, and cardiac dysfunction were
eliminated in 5- to 6-week-old dKO mice by probucol treatment.
Effects of Probucol Treatment on Lipoproteins and RBC Maturation.
Probucol treatment lowered by 2-fold the levels of plasma TC
(Table 1) and PLs (Table 2) in dKO mice compared to those in
untreated apoE KO mice (also see refs. 28 and 35). Treatment
did not lower the plasma triglyceride level of dKO mice that was
somewhat lower than that of apoE KO mice (Table 2). The
lipoprotein TC profile (FPLC size fractionation, Fig. 4A) of dKO
mice (Fig. 4A, filled circles) has been described (16). The
abnormally large HDL particles in dKO mice are found in
the VLDLintermediate-density lipoproteinsLDL, but not
the HDL, size ranges, because of the loss of SR-BI-mediated
selective lipid uptake (15, 16). Unexpectedly, probucol treat-
ment (Fig. 4A, open circles) induced the appearance of a peak
of cholesterol at the position of normal-sized HDL (fractions
29–34) that contained apoA-I (preliminary analysis, data not
shown) that is also seen in untreated apoE KO mice (data not
shown; refs. 16 and 42). In contrast, probucol decreases the
normal-size HDL peak in apoE KO mice (28). Determination of
the mechanism for probucol-induced reappearance of the nor-
mal-sized HDL-like particles seen in all eight dKO-P animals
examined [e.g., induced SR-BI independent selective lipid up-
take (ref. 43, reviewed in ref. 2)] awaits further studies. The
shapes of the lipoprotein UC and PL FPLC profiles (data not
shown) were similar to that of TC. The ratios of the relative
amounts of UC to TC and PL to TC in the major FPLC
lipoprotein fractions are shown in Table 2.
Fig. 3. Histologic analysis of hearts. (A–F) Representative longitudinal sec-
tions of hearts from 6-week-old untreated dKO (A and D), probucol-treated
dKO-P (B and E), and untreated apoE single KO (C and F) mice stained with
Masson’s trichrome (healthy myocardium, red; fibrotic infarcted tissue, blue).
(G and H) Oil red O-stained sections through the aortic sinuses of probucol-
treated dKO (G) and apoE KO (H) mice. (Scale bars: A–C, 1 mm; D–F, 10 m; G
and H, 100 m.)
Fig. 2. Effects of probucol on heart function and size. Parental and offspring mice were fed either a low-fat chow or probucol (0.5% wt-wt)-supplemented
diet. (A) Representative short-axis MRI images of hearts from mice (Upper, untreated dKO, n  4; Lower, probucol-treated dKO-P, n  5) at end diastole (Left)
and end systole (Right). Blood-filled heart chambers are white, and arrows indicate left ventricles (LV). (B) Representative ECGs from 6-week-old unanesthetized,
untreated (Upper, dKO; ref. 1) or probucol-treated (Lower, dKO-P, n  11) mice. (C) Mean values (standard deviations) of heart weights normalized to body
weights for 6-week-old untreated (Left) or probucol-treated (Right) apoE KO (open bars) and dKO (filled bars) mice. Untreated dKO hearts were statistically
different from the others (*, P  0.0001, ANOVA test). Probucol treatment significantly altered the weights of dKO (P  0.0001, t test) but not apoE KO (P  0.09)
hearts. Numbers of mice studied were: dKO, 18; dKO-P, 11; apoE KO, 8; and apoE KO-P, 4.











There was a surprisingly high ratio of UC to TC in both dKO
and SR-BI KO mice compared with SR-BI-positive controls
(Table 1). As a consequence in dKO mice the ratio of surface
polar (UC and PL) to corenonpolar (esterified cholesterol and
triglycerides) lipids was 6-fold larger than in apoE KO controls
(Table 2). This high ratio suggested that the structures of the
lipoproteins in dKO mice would be abnormal. Electron micro-
graphs of negatively stained total plasma (not shown) and major
lipoprotein fractions from dKO mice (Fig. 4B Upper) showed the
presence of numerous lamellarvesicular (Fig. 4B Upper, ar-
rows), and stacked discoidal (Fig. 4B Upper, arrowheads) par-
ticles with abnormal morphologies, reminiscent of those (e.g.,
lipoprotein-X) seen in LCAT deficiency, cholestasis, and other
cases of abnormally high UC (32–34). The large probucol-
induced decrease (4.8-fold) in plasma UC lowered the abnor-
mally high ratios of UCTC in both dKO and SR-BI KO mice
to the normal values in SR-BI-positive controls (Table 1) and
lowered the surface-to-core lipid ratio in dKO mice to that in
apoE KO controls (Table 2). As a consequence, the morphol-
ogies of the major lipoprotein fractions in dKO-P mice (Fig. 4B
Lower) were restored to those in apoE KO controls (data not
shown; ref. 34). The mechanisms underlying the abnormally high
UC in untreated SR-BI-negative mice, its reversal by probucol,
and its relevance to pathology in dKO mice are uncertain.
There is a profound, reversible defect in RBC maturation in
dKO mice caused by excessive accumulation in precursor re-
ticulocytes of UC (visualized by staining with the cholesterol-
binding, f luorescent dye filipin, see Fig. 5 and Table 3, ref. 22).
Compared with WT (data not shown, ref. 22) and apoE KO
mice, the untreated dKO mice were anemic and exhibited
profound reticulocytosis (irregularly shaped, precursor reticulo-
cytes, no biconcave mature erythrocytes). Their large, macro-
cytic red cells (elevated mean copuscular volume) differed
morphologically from classic abnormal ‘‘target’’ cells seen in
LCAT-deficient patients (unpublished data; refs. 44 and 45) and
contained big, cholesterol-rich autophagolysosomal inclusion
bodies (22). Almost all of these abnormalities, except the
somewhat irregular shape (Fig. 5 Upper Right), were corrected by
probucol treatment. Correction of the reticulocytosis in dKO
mice by probucol may contribute to its suppression of their CHD,
e.g., by improving tissue oxygenation.
Discussion
Mice with homozygous null mutations in the HDL receptor
SR-BI and apoE genes (dKO mice) on a low-fat diet rapidly
Table 1. Effects of probucol on plasma UC and TC
Genotypedrug
treatment UC, mg/dl TC, mg/dl Ratio (UC/TC)
DKO
None (n  11) 781  65*† 970  83*† 0.806  0.007*†
Probucol (n  10) 151  21 456  45 0.318  0.013
SR-BI/ apoE KO
None (n  5) 124  11§ 421  31¶ 0.296  0.012‡
Probucol (n  5) 57  3 244  20 0.238  0.015
apoE KO
None (n  5) 126  14§ 433  66¶ 0.291  0.02
Probucol (n  3) 69  6 249  8 0.277  0.02
SR-BI KO**
None (n  13) 108  5 211  6 0.515  .027
Probucol (n  13) 24  2 110  6 0.218  .012
WT control**
None (n  7) 33  2 103  4 0.315  .011
Probucol (n  7) 8  2 34  4 0.222  .033
Data are represented as mean  standard error: *P  0.0001, compared
with all the other groups with ANOVA test. P values for t test comparison with
or without probucol treatment: †, 0.0001; ‡, 0.020; §, 0.0003; ¶, 0.0031;
, 0.35.
**Blood samples from 4- to 5-week-old animals fed a low-fat chow diet were
drawn, the same animals were fed a probucol supplemented diet for an
additional 7–25 days, and a second set of samples was drawn (TC data are
from ref. 35).
Table 2. Effects of probucol on plasma PL, triglyceride, and
lipid ratios
dKO dKO  probucol apoE KO
Plasma PL, mg/dl 678  96 (n  8) 246  95 (n  3) 307  51 (n  9)
Plasma triglyceride,
mg/dl
53  16 (n  4) 60  44 (n  3) 89  28 (n  6)
UC  100TC to
PL  100TC ratio
Plasma* 86:60 43:61 30:68
VLDL* 83:55 41:52 35:56
IDL/LDL* 79:60 37:51 36:62





*Average of three (dKO and dKO-P) or two (apoE KO) independent determi-
nations from individual mice. The amounts of the indicated lipids in each of
the major lipoproteins [VLDL, fractions 3–9; intermediate-density lipopro-
tein (IDL)LDL, fractions 10–26; HDL fractions 30–37] from the FPLC profiles
were added together, and the averages were used to calculate the relative
amounts of UC to TC (UC  100TC) and PL to TC (PL  100TC).
†(PL  UC)(esterified cholesterol  triglycerides).
Fig. 4. Lipoprotein cholesterol profiles and morphology. Parental and off-
spring mice were fed a low-fat chow diet without or with probucol [0.5%
(wtwt) supplementation]. (A) Representative chromatograms of the TC
(mgdl of plasma) from size-fractionated (Superose 6-FPLC) plasma lipopro-
teins from 6-week-old untreated dKO (F) or probucol-treated dKO (E) mice
are shown with the approximate elution positions of VLDL, intermediate-
density lipoproteins (IDL)LDL, and HDL. (Inset) Expanded HDL region. (B)
Electron micrographs of negatively stained lipoproteins from pooled FPLC
fractions. Abnormal morphologies are indicated by arrows (lamellar
vesicular), arrowheads (stacked discoidal), and asterisks (aggregated). (Scale
bar  60 nm.)
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develop many cardinal features of human CHD, including
hypercholesterolemia, atherosclerosis in the aortic sinus, occlu-
sive coronary plaques, patchy MIs, cardiac enlargement and
dysfunction (reduced systolic function and ejection fraction,
ECG abnormalities), and premature death (50% mortality at 6
weeks) (1, 16). They also exhibit a block in RBC maturation (22).
Their abnormally high ratio of lipoprotein surface (UC, PLs) to
core (esterified cholesterol, triglycerides) lipids led to abnormal
lipoprotein morphology (lamellarvesicular and stacked discoi-
dal particles reminiscent of those in other cases of high UC, e.g.,
LCAT deficiency, cholestasis, and apoEhepatic lipase defi-
ciency; refs. 32–34). The mechanism causing excess UC in SR-BI
null (dKO, SR-BI KO) mice is unknown, but may involve the
activities of LCAT, hepatic lipase, or other lipoprotein-
metabolizing proteins (32–34).
Treatment of dKO mice with the lipid-lowering and antioxida-
tion drug probucol (25–27) extended their lives (from 6 to 36 weeks)
and reversed essentially all early-onset CHD-associated anatomical,
functional, cellular, and biochemical pathology. A substantial por-
tion of the probucol-sensitive pathology apparently occurred be-
tween 3 and 5 weeks of age. Potential mechanisms by which
probucol treatment may have reduced atherosclerosis andor CHD
(16, 25–27, 30) in dKO mice include its ability to: (i) alter lipopro-
tein metabolism (25–28, 30), especially lowering TC and normal-
izing the UCTC ratio (latter effect not observed in humans, ref.
46), and lipoprotein morphology, (ii) reduce the relative amounts
of atherogenic versus antiatherogenic lipoproteins, possibly by
inducing alternative cellular pathways of lipoprotein metabolism
and restoring production of normal-size HDL, (iii) alter lipid
metabolismtransport in the artery wall, (iv) prevent RBC matu-
ration defects and thus associated hypoxia (probably caused by
altered lipoprotein compositionabundance), (v) counter effects of
SR-BI deficiency on cellular metabolism, e.g., HDLSR-BI-
mediated regulation of endothelial NO synthase in endothelial cells
(47, 48), and (vi) exhibit antioxidant, antiinflammatory, antihy-
poxia, or other lipid-lowering independent activities (25–27, 31,
49–57). Indeed, while this manuscript was in preparation, several
groups reported beneficial influences of probucol in atherosclero-
sis-independent models of heart failure involving tachycardia (58)
or coronary ligation (59). Probucol also protects against adriamy-
cin-induced heart failure (60). Unfortunately, the detailed molec-
ular mechanisms underlying probucol’s diverse activities are not
well understood (25–27, 61). Probucol’s striking effects on choles-
terol metabolism (UCTC ratio) and lipoprotein morphology were
likely to have played a key role in its cardioprotective effects and
may help uncover its mechanism of action.
Although the rapid onset of CHD in dKO mice has many
experimental advantages (1), it may, in some cases, complicate
analysis of the influence of relatively slow processes, such as
therapeutic angiogenesis. Varying the time andor dosage of
probucol administration can be used as a switch or rheostat to
start, stop, or alter disease progression and thus make this model
more useful.
In summary, the dKO mouse model of CHD exhibits many
cardinal features of the human disease (1, 16). Probucol, a drug
previously used to treat human hyperlipidemia and atheroscle-
rosisrestenosis, can effect a virtually complete short-term cure
and be used to alter the time of death, thus enhancing the
usefulness of this model. This system should help in further
Fig. 5. Effects of probucol on RBCs. RBCs from 5-week-old untreated () or probucol-treated () apoE KO and dKO mice were examined by either transmission
electron microscopy (Upper) or confocal fluorescence microscopy after staining with the cholesterol-binding, blue fluorescing dye filipin (Lower). [Scale bar
(Upper)  2 m; magnification (Lower)  100.)











None (n  8) 52.5  2.1 57.6  0.5 2.8  1.2
Probucol (n  3) 49.8  1.5 54.2  2.1 4.1  0.8
dKO
None (n  6) 34.2  1.7 84.1  4.1 100  0
Probucol (n  3) 50.8  2.4 54.2  2.3 4.1  0.5
All animals were 4–6 weeks old, except one each of probucol-treated dKO
and apoE KO that were 6 months old. All values are means  standard
deviations. All of the values from the untreated dKO mice were significantly
different from those from the other three groups (P  0.0001 for mean
corpuscular volume and percentage reticulocytes; P  0.001 for hematocrit).
Normal mouse reticulocyte counts range from 2% to 6%. Data for untreated
animals are from ref. 22.











investigations of the pathophysiology of CHD and be valuable
for preclinical testing of new approaches for the prevention and
treatment of cardiovascular disease.
Note Added in Proof: A paper in press (62) independently reports a high
UCTC ratio (0.5) in SR-BI single KO mice as described here.
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